Life reinsurance
-
The sidecar was launched today by the Bermudian reinsurer and investment firm Carlyle. -
The capital will provide retro cover for life-focused reinsurer Fortitude Re.
-
The Bermuda firm said HS Sawmill reflected its continued focus on life insurance.
-
He joined what was then Credit Suisse ILS in 2019, moving from Hiscox Re & ILS.
-
The executive formerly served in senior leadership roles at Nomura, Credit Suisse and Goldman Sachs.
-
GP Affluent Markets will look to serve high-net-worth individuals.
-
Tom Fealey has assumed lead portfolio manager responsibilities.
-
The reinsurer has made improvements to its life and health segment, it said.
-
Spread guidance anticipates a lower multiple compared to 2024’s Vitality Re issuance.
-
The ILS manager will “pragmatically accept” a degree of credit risk in deals.
-
The sidecar was established to enhance RGA’s access to capital for its US asset intensive business.
-
The ILS manager claims that 777 Partners “double-pledged” collateral.
-
The fund is a continuation vehicle for five of HSCM's life insurance interests.
-
The investment firm said cat bond spreads that are elevated relative to historical levels continue to offer an attractive entry point for investors.
-
A market-wide loss of $700mn would amount to around 15% of the total amount of life ILS assets under management .
-
The life segment has shifted from its genesis in mortality and morbidity risk transfer as lapsed risk deals have proliferated.
-
The Zurich-based ILS manager has entered a partnership with the new life ILS firm set up by former Securis CUO Paul Whiting.
-
The issuance is a similar size to that of 2021 and significantly larger than that of 2020.
-
The target price and size are broadly flat with last year’s deal, although it is hoping to make some savings on the lower-risk layer.
-
The mortality cat bond will again include Covid-19 cover, as was the case with the debut issuance last year.
-
The Berkshire Hathaway-owned carrier is looking to make “major contributions” to the region.
-
The injection leaves US private equity firm Golden Gate Capital as a controlling shareholder.
-
The deal will be one of only two standalone mortality bonds on risk when it completes
-
Some fund managers were negative on the deal, given the continuing uncertainty caused by the Covid-19 pandemic.
